With regard to the empiric use of gonadotropin releasing hormone (GnRH) agonist or antagonist, it is not recommended in adolescents with chronic pelvic pain and suspected endometriosis, due to potential impact on bone density, in contrast to adulthood [59]. Here, GNRH1 is linked to endometriosis.